Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been formally appointed as a director. This appointment comes pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The changes are designed to ensure that the board continues to meet Helix's evolving governance and capital markets requirements, and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in future endeavors.
These governance adjustments are pivotal for Helix as it progresses its pipeline, which is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The appointment of Dr. Mehrling to the board aligns leadership with the company's strategic direction, particularly following the Laevoroc acquisition, which brought in promising pre-IND candidates. This move is expected to enhance board oversight and provide direct insight from the CEO, potentially accelerating decision-making and reinforcing investor confidence.
Helix BioPharma's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit the company's website at https://www.helixbiopharma.com/. Additional details on the acquisition can be found at https://www.helixbiopharma.com/fy2025/helix-biopharma-secures-pre-ind-candidates-leumuna-and-gemceda-in-strategic-acquisition-from-the-laevoroc-group/.
These board changes come at a critical time for Helix, as the company continues to advance its clinical programs and integrate its recent acquisition. The addition of Dr. Mehrling to the board underscores a commitment to strong governance and strategic alignment, which are essential for navigating the complexities of oncology drug development and capital markets.
